1-4 of 4
Harpreet Singh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Available to Purchase
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-Gonzalez, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Journal: Cancer Immunology Research
Cancer Immunol Res (2023) 11 (7): 925–945.
https://doi.org/10.1158/2326-6066.CIR-22-0444
Published: 05 July 2023
View articletitled, Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Open the PDF for Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC

Free
Andrea Mayer-Mokler, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Francesco Izzo, Alfred Koenigsrainer, Markus Loeffler, Christian Flohr, Phillip Mueller, Sarah Kutscher, Hans-Georg Rammensee, Bruno Sangro, Sven Francque, Danila Valmori, Toni Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Harpreet Singh, Luigi Buonaguro
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11_Supplement): A043.
https://doi.org/10.1158/2326-6066.IMM2016-A043
Published: 31 October 2016
View articletitled, Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC
Journal Articles

Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC

Free
Luigi Buonaguro, Sarah Kutscher, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Francesco Izzo, Alfred Koenigsrainer, Markus Loeffler, Phillip Mueller, Andrea Mayer, Hans-Georg Rammensee, Bruno Sangro, Sven Francque, Danila Valmori, Toni Weinschenk, Harpreet Singh-Jasuja
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): A115.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A115
Published: 03 January 2016
View articletitled, Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC
Journal Articles

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

Available to Purchase
Christopher R. Heery, B. Harpreet Singh, Myrna Rauckhorst, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Timothy C. Rodell, William Dahut, Philip M. Arlen, Ravi A. Madan, Jeffrey Schlom, James L. Gulley
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (11): 1248–1256.
https://doi.org/10.1158/2326-6066.CIR-15-0119
Published: 04 November 2015
View articletitled, Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Open the PDF for Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury in another window
Includes: Supplementary data